



Published by the Pharmaceutical Services Division to provide information for British Columbia's health care providers

QuickLinks

Keeping the Lines Clear 1

Newsletter Notification Service 1

Special Services Fees 2

Low Cost Alternative (LCA) / Reference Drug Program (RDP) Booklet Changes 2

New LCA Categories 4

Benefits – Amlodipine Besylate 5

KEEPING THE LINES CLEAR



Please do not share PharmaNet Help Desk numbers with patients.

Instead, refer patients to the Health Insurance BC public phone lines or the PharmaCare website at www.health.gov.bc.ca/pharmacare

NEWSLETTER NOTIFICATION SERVICE


Sign up for our e-mail notification service and you'll be the first to know when a newsletter or bulletin has been posted on our website.

To subscribe/unsubscribe:

- Visit the PharmaCare website Newsletter page at www.health.gov.bc.ca/pharmacare/newsletter/index.html.
- Near the top of the page, click on [Subscription Service](#).

Already subscribed to the service? If your e-mail address changes, please unsubscribe your old address before subscribing with your new e-mail address.

Still getting printed copies you don't actually need? Please call the PharmaNet HelpDesk and ask to be removed from the 'hard copy' mailing list.



**The use of PharmaNet is not intended as a substitute for professional judgment.
 Information on PharmaNet is not exhaustive and cannot be relied upon as complete.
 The absence of a warning about a drug or drug combination is not an indication that the drug or drug combination is safe, appropriate or effective in any given patient.
 Health care professionals should confirm information obtained from PharmaNet, and ensure no additional relevant information exists, before making patient care decisions.**

SPECIAL SERVICES FEES

The number of Special Services fees that PharmaCare paid each month over the past year:

Aug 2009.....2,212	Apr 2009..... 2,347	Dec 2008 3,526
Jul 2009.....2,619	Mar 2009..... 2,252	Nov 2008 3,079
Jun 20092,554	Feb 2009 2,100	Oct 2008..... 3,309
May 20092,357	Jan 2009 2,131	Sep 2008 2,972

LOW COST ALTERNATIVE (LCA) / REFERENCE DRUG PROGRAM (RDP) BOOKLET CHANGES

Effective **October 27, 2009**, the following LCA categories (including both existing and new PharmaCare benefits) will be revised.

NEW CATEGORY (CHEMICAL NAME)	DIN	BRAND NAME	LCA STATUS	PRICE
GLICLAZIDE TAB 80mg (The LCA price for this category is set at the LCA price of the new LCA category for GLICLAZIDE MR 30mg TAB.)	02245247	APO-GLICLAZIDE	P* (NO CHANGE)	0.1458
	00765996	DIAMICRON	P* (NO CHANGE)	0.1458
	02229519	MYLAN-GLICLAZIDE	P*	0.1458
	02155850	GLICLAZIDE	P* (NO CHANGE)	0.1458
	02238103	NOVO-GLICLAZIDE	P*	0.1458
	02294400	PMS-GLICLAZIDE	P* (NO CHANGE)	0.1458
	02254719	SANDOZ-GLICLAZIDE	P* (NO CHANGE)	0.1458
RISPERIDONE ORAL SOL 1mg/ml	2280396	APO-RISPERIDONE	P	0.5729
	2279266	PMS-RISPERIDONE	P	0.5729
	2236950	RISPERDAL	F	
RISPERIDONE TAB 0.25mg	2282119	APO-RISPERIDONE	P	0.2153
	2282585	CO-RISPERIDONE	P	0.2153
	2282240	MYLAN-RISPERIDONE	P	0.2153
	2282690	NOVO-RISPERIDONE	P	0.2153
	2252007	PMS-RISPERIDONE	P	0.2153
	2280906	RAN-RISPERIDONE	P	0.2153
	2264757	RATIO-RISPERIDONE	P	0.2153
	2240551	RISPERDAL	F	
	2292807	SANDOZ-RISPERIDONE	P	0.2153

NEW CATEGORY (CHEMICAL NAME)	DIN	BRAND NAME	LCA STATUS	PRICE
RISPERIDONE TAB 0.5mg	2282127	APO-RISPERIDONE	P	0.3606
	2282593	CO-RISPERIDONE	P	0.3606
	2282259	MYLAN-RISPERIDONE	P	0.3606
	2264188	NOVO-RISPERIDONE	P	0.3606
	2252015	PMS-RISPERIDONE	P	0.3606
	2280914	RAN-RISPERIDONE	P	0.3606
	2264765	RATIO-RISPERIDONE	P	0.3606
	2240552	RISPERDAL	F	
	2279495	SANDOZ-RISPERIDONE	P	0.3606
RISPERIDONE TAB 1mg	2282135	APO-RISPERIDONE	P	0.4982
	2282607	CO-RISPERIDONE	P	0.4982
	2282267	MYLAN-RISPERIDONE	P	0.4982
	2264196	NOVO-RISPERIDONE	P	0.4982
	2252023	PMS-RISPERIDONE	P	0.4982
	2280922	RAN-RISPERIDONE	P	0.4982
	2264773	RATIO-RISPERIDONE	P	0.4982
	2025280	RISPERDAL	F	
	2279800	SANDOZ-RISPERIDONE	P	0.4982
RISPERIDONE TAB 2mg	2282143	APO-RISPERIDONE	P	0.9946
	2282615	CO-RISPERIDONE	P	0.9946
	2282275	MYLAN-RISPERIDONE	P	0.9946
	2264218	NOVO-RISPERIDONE	P	0.9946
	2252031	PMS-RISPERIDONE	P	0.9946
	2280930	RAN-RISPERIDONE	P	0.9946
	2264781	RATIO-RISPERIDONE	P	0.9946
	2025299	RISPERDAL	F	
	2279819	SANDOZ-RISPERIDONE	P	0.9946

NEW CATEGORY (CHEMICAL NAME)	DIN	BRAND NAME	LCA STATUS	PRICE
RISPERIDONE TAB 3mg	2282151	APO-RISPERIDONE	P	1.4920
	2282623	CO-RISPERIDONE	P	1.4920
	2282283	MYLAN-RISPERIDONE	P	1.4920
	2264226	NOVO-RISPERIDONE	P	1.4920
	2252058	PMS-RISPERIDONE	P	1.4920
	2280949	RAN-RISPERIDONE	P	1.4920
	2264803	RATIO-RISPERIDONE	P	1.4920
	2025302	RISPERDAL	F	
	2279827	SANDOZ-RISPERIDONE	P	1.4920
RISPERIDONE TAB 4mg	2282178	APO-RISPERIDONE	P	1.9894
	2282631	CO-RISPERIDONE	P	1.9894
	2282291	MYLAN-RISPERIDONE	P	1.9894
	2264234	NOVO-RISPERIDONE	P	1.9894
	2252066	PMS-RISPERIDONE	P	1.9894
	2280957	RAN-RISPERIDONE	P	1.9894
	2264811	RATIO-RISPERIDONE	P	1.9894
	2025310	RISPERDAL	F	
	2279835	SANDOZ-RISPERIDONE	P	1.9894

F – Fully covered
P – Partially covered

P* – Drug is a partial benefit if Special Authority is in place when the prescription is filled.

NEW LCA CATEGORIES

The following drugs (including both existing and new PharmaCare benefits) will be included as a new LCA category on PharmaNet, effective **October 27, 2009**.

NEW CATEGORY (CHEMICAL NAME)	DIN	BRAND NAME	LCA STATUS	PRICE
GLICLAZIDE MR 30mg TAB	02297795	APO-GLICLAZIDE MR	F*	
	02242987	DIAMICRON MR	F*	

F* - Drug is a full benefit if Special Authority is in place when the prescription is filled.

BENEFITS – AMLODIPINE BESYLATE

The following generic amlodipine besylate products are:

- subject to the [Multiple-Source Generics Pricing Policy](#) as of **September 15, 2009**, and
- included in the existing LCA Categories and the Reference Drug Program effective **September 15, 2009**.

NEW CATEGORY (CHEMICAL NAME)	DIN	BRAND NAME	LCA STATUS	LCA PRICE	RDP STATUS	COST REDUCTION FACTOR
AMLODIPINE BESYLATE TAB 5mg	02280132	GD-AMLODIPINE	P**		P	4.00%
AMLODIPINE BESYLATE TAB 10mg	02280140	GD-AMLODIPINE	P**		P	4.00%

P** – Drug is a full benefit if RDP Special Authority is in place when the prescription is filled.